21智讯01月12日电，汉宇集团公告，公司近日接到控股股东石华山先生通知，获悉其所持有公司的部分 股份解除质押，本次解除质押股份数量为11,140,000股，占其所持股份比例的5.57%，占公司总股本比 例的1.85%。本次解除质押的质权人为国泰海通证券股份有限公司，解除日期为2026年1月9日。截至该 日，石华山先生累计持有公司股份199,962,277股，持股比例为33.16%，累计被质押股份数量为 45,500,000股，占其所持股份的22.75%。 ...

21智讯01月12日电，德科立公告，根据2026年1月12日询价申购情况，公司股东钱明颖女士本次询价转 让初步确定的转让价格为126.35元/股。参与报价的机构投资者经出让方与组织券商国泰海通证券股份 有限公司协商，一致决定启动追加认购程序，追加认购截止时间不晚于2026年1月16日。受让方通过询 价转让受让的股份，在受让后6个月内不得转让。 ...

截至公告披露日，王万里直接持有公司股份5,775股，占公司总股本的比例为0.0052%，上述股份来 源为集中竞价交易买入及公司利润分配资本公积转增股本取得，均为无限售条件流通股。 本次减持股份计划不会对公司治理结构及持续经营产生重大影响，不会导致上市公司控制权发生变 更。 中国经济网北京1月12日讯 创耀科技（688259.SH）昨日晚间披露《董事、副总经理、核心技术人 员减持股份计划公告》。 根据公告，公司董事、副总经理、核心技术人员王万里计划自公告披露之日起15个交易日后的3个 月内，通过集中竞价交易方式减持不超过1,443股，占公司总股本比例不超过0.0013%，且不超过其减持 前所持有公司股份总数的25%。减持期间为2026年2月3日至2026年5月2日。 创耀科技首次公开发行股票的发行费用总额为1.12亿元，其中保荐及承销费用8800.00万元。 创耀科技2024年年报显示，公司的控股股东为重庆创睿盈企业管理有限公司，实际控制人为 YAOLONG TAN，为美国国籍。 2023年年度权益分派实施公告显示，以方案实施前公司总股本80,000,000股扣减股权登记日公司回 购专用证券账户中的750,00 ...

2025年我国资本市场融资融券业务大幅增长，成为市场活跃度提升的核心风向标。 数据显示，2025年全年新开两融账户达154.21万户，如何看待这一数字？ 154.21万户创下近十年以来的最高纪录，较2024年增加了53.36万户，增幅超52%，较2018年的阶段性低点40.34万户增长近3.8倍。 2025年末两融账户总数突破1564万户，较2024年末实现跨越式增长。 截至2025年末，全市场融资余额从2024年末的1.85万亿元升至2.52万亿元，增幅超36%，投资者参与两融业务的热情高涨。 从时间维度看，2025年两融开户节奏稳健且下半年发力明显，9月以20.54万户创下全年单月新高，8月、3月、11月、12月新开账户数均 超14万户。这一增长态势是市场需求与券商布局共振的结果，全年行业两融业务增幅集中在25%-40%，头部券商与区域中型券商各展优 势，多家券商上调业务规模上限以承接需求。 资金流向呈现鲜明导向， 硬科技与高端制造业成为核心赛道，硬件设备、半导体、电气设备等行业融资净买入占比显著， 新易盛、中际旭 创等科技类龙头企业备受青睐，资金配置与国家产业升级方向高度契合，展现出杠杆资金对优质核心资 ...

Market Performance - A-shares experienced a strong rebound on January 12, with the Shanghai Composite Index rising by 0.75% to 4151.14 points and the Shenzhen Component Index increasing by 1.31% to 14305.10 points, while the ChiNext Index rose by 1.17% to 3366.71 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.31 trillion yuan, an increase of 245.5 billion yuan compared to the previous trading day [1] Sector Highlights - AI applications continued to surge, with stocks like Worth Buying and Guangyun Technology hitting the daily limit [1] - The commercial aerospace sector remained strong, with companies like Luxin Investment achieving 10 consecutive trading limits [1] - The photovoltaic sector was active, with Dongfang Risheng reaching a 20% limit up [1] - Retail concepts also saw gains, with Maoye Commercial and Sanjiang Shopping both hitting the daily limit [1] - In contrast, sectors such as oil and gas, and coal experienced significant declines [2] Institutional Insights - Huatai Securities noted that the A-share market continued to rise with increased trading volume, indicating a spring rally driven by heightened risk appetite [3] - The report suggested focusing on high-cost performance sectors, particularly in gaming, duty-free, batteries, engineering machinery, and agricultural chemicals [3] - CITIC Construction emphasized the rapid development of the AI industry, highlighting the potential for new application waves driven by advancements in model capabilities [3][4] Government Policy - The National Development and Reform Commission issued guidelines for government investment funds, marking the first systematic regulation on fund allocation and investment direction [5] - The guidelines emphasize supporting major strategic areas and fostering new pillar industries while avoiding investments in restricted or obsolete sectors [5] Storage Market Outlook - Counterpoint Research reported that the storage market has entered a "super bull market," with prices expected to rise by 40%-50% in Q1 2026 and an additional 20% in Q2 2026 due to surging demand from AI and server capacities [6][7]

2025年我国资本市场融资融券业务大幅增长，成为市场活跃度提升的核心风向标。 数据显示，2025年全年新开两融账户达154.21万户，如何看待这一数字？ 154.21万户创下近十年以来的最高纪录，较2024年增加了53.36万户，增幅超52%，较2018年的阶段性低点40.34万户增长近3.8倍。2025年末两融账户总数突 破1564万户，较2024年末实现跨越式增长。 截至2025年末，全市场融资余额从2024年末的1.85万亿元升至2.52万亿元，增幅超36%，投资者参与两融业务的热情高涨。 从时间维度看，2025年两融开户节奏稳健且下半年发力明显，9月以20.54万户创下全年单月新高，8月、3月、11月、12月新开账户数均超14万户。这一增长 态势是市场需求与券商布局共振的结果，全年行业两融业务增幅集中在25%-40%，头部券商与区域中型券商各展优势，多家券商上调业务规模上限以承接需 求。 资金流向呈现鲜明导向，硬科技与高端制造业成为核心赛道，硬件设备、半导体、电气设备等行业融资净买入占比显著，新易盛、中际旭创等科技类龙头企 业备受青睐，资金配置与国家产业升级方向高度契合，展现出杠杆资金对优质核心资产的 ...

Core Viewpoint - The insurance sector is expected to experience high growth on the liability side, particularly through the bancassurance channel, while benefiting from the spring market rally, indicating a sustained bullish trend for insurance stocks [1][6]. Group 1: Market Activity and Trends - January saw a strong market opening with significant trading activity, as the average daily stock fund turnover exceeded 30 trillion yuan, marking a year-on-year increase of 137% [2]. - The financing balance and margin balance recorded 2,609.9 billion yuan and 17.7 billion yuan respectively, reflecting increases of 3.4% and 6.9% compared to the previous week [2]. - The average daily margin balance since 2026 reached 2,598.7 billion yuan, showing a year-on-year growth of 42% [2]. Group 2: M&A Market Performance - The M&A market in 2025 demonstrated strong performance with a total of 8,151 disclosed M&A events, a slight decrease of 0.72% year-on-year, while the total transaction value reached approximately 25,894 billion yuan, representing a year-on-year increase of 16.12% [3]. Group 3: Investment Recommendations - Focus on undervalued brokers that are expected to rebound during the spring market rally, with strong recommendations for quality brokers like Guotai Junan [4]. - Attention is drawn to Sichuan Shuangma, which is positioned well in the technology sector and is expected to benefit from investments in gene therapy [4]. - Highlighting the impressive growth rates of diversified financial companies, recommendations include Yixin Group, Far East Horizon, and Jiufang Zhitu Holdings [4]. Group 4: Bancassurance Growth Drivers - The shift of deposits to insurance is anticipated to drive significant growth in the bancassurance channel, with projected incremental funds of 3,057 billion yuan in January, 5,094 billion yuan in Q1, and 11,150 billion yuan for the entire year of 2026, corresponding to growth rates of 91%, 59%, and 28% respectively [5]. - The growth of leading insurance companies is expected to outpace the market due to stricter product entry requirements and improved profitability in the bancassurance channel [5]. Group 5: Long-term Outlook for Insurance Sector - The insurance sector is entering a phase of simultaneous volume and price increases on the liability side, driven by the migration of deposits and strong demand for retirement savings [6]. - The stability or improvement of the stock market and interest rates is crucial for supporting the expansion of large insurance companies' balance sheets [6].

Core Viewpoint - The insurance sector is expected to experience high growth on the liability side, particularly through the bancassurance channel, while benefiting from the spring market rally, leading to a sustained performance in insurance stocks [1][6]. Group 1: Market Activity - The market welcomed the new year with increased trading activity, with daily stock fund turnover exceeding 30 trillion yuan, a significant year-on-year increase of 137% [2]. - As of January 9, the financing and margin trading balances reached 2,609.9 billion yuan and 17.7 billion yuan, respectively, marking increases of 3.4% and 6.9% from the previous week [2]. - The average daily margin trading balance since 2026 has been 2,598.7 billion yuan, reflecting a year-on-year growth of 42% [2]. Group 2: M&A Market Performance - The M&A market in China showed strong performance in 2025, with a total of 8,151 disclosed M&A events, a slight decrease of 0.72% year-on-year, while the total transaction value reached approximately 25,894 billion yuan, representing a year-on-year increase of 16.12% [3]. Group 3: Investment Recommendations - Focus on undervalued brokers that are expected to rebound during the spring market rally, with strong recommendations for quality brokers with significant valuation and performance mismatches, particularly Guotai Junan [4]. - Attention should also be given to Sichuan Shuangma, which is positioned well in the technology sector and is expected to benefit from investments in gene therapy [4]. - Highlighting the impressive growth rates in diversified financial services, companies like Yixin Group, Far East Horizon, and Jiufang Zhitu Holdings are recommended for investment [4]. Group 4: Bancassurance Growth - The bancassurance channel is projected to be a major driver of new business and new business value (NBV) growth in 2026, with a significant increase in household savings since 2020 [5]. - The estimated incremental funds for the bancassurance channel in January, Q1, and the entire year of 2026 are 305.7 billion yuan, 509.4 billion yuan, and 1,115 billion yuan, respectively, with growth rates of 91%, 59%, and 28% [5]. - Larger insurance companies are expected to outperform in growth due to stricter product entry requirements and improved profitability in the bancassurance channel [5]. Group 5: Long-term Outlook - The insurance sector is entering a favorable cycle with simultaneous increases in volume and price, driven by the migration of deposits and strong demand for retirement savings [6]. - The cost of existing liabilities is expected to decrease, while new policies will benefit from favorable interest spreads, supporting the expansion of large insurance companies [6].

Group 1 - The core viewpoint is that Guotai Junan Securities maintains an "overweight" rating for Weigao Co., Ltd. (01066) and sets a target price of HKD 7.84, as Weigao Blood Products plans to acquire 100% of Weigao Purui's shares, positioning itself as the controlling shareholder and flagship platform for medical devices within the group [2][3] - The acquisition is expected to be completed in the second half of 2026, with Weigao Blood Products currently holding 23.53% of Weigao Co. and 94.07% of Weigao Purui prior to the transaction [3] - The assessed value of Weigao Purui's 100% equity is estimated at CNY 8.511 billion, with a share issuance price of CNY 31.29 per share, leading to the issuance of 272 million shares, which will constitute 39.43% of the total post-issuance share capital [3] Group 2 - The upstream biopharmaceutical market is expanding rapidly, with a projected market size of CNY 21.2 billion in 2024 and a compound annual growth rate (CAGR) of 11.5% expected from 2024 to 2030, indicating significant opportunities for domestic substitution [4] - Weigao Blood Products has established a product line for upstream biopharmaceutical filtration, while Weigao Purui possesses extensive customer resources in the biopharmaceutical sector, suggesting potential synergies post-acquisition [4] - Following the transaction, Weigao Co. will hold 52.10% of Weigao Blood Products, becoming its controlling shareholder and further clarifying its position as the flagship platform for medical devices under the Weigao brand [5]

智通财经APP获悉，国泰海通证券发布研报称，维持威高股份(01066)"增持"评级，给予目标价7.84港 元，威高血净拟发行股份收购威高普瑞全部股权，通过此次整合，威高股份将成为威高血净的控股股 东，进一步明确其作为集团旗下医疗器械旗舰平台的定位。双方有望在生物制药上游领域形成协同，把 握国产替代机遇，拓展增长空间，交易预计在2026年中后期完成。 根据公司投资者演示材料，2024下半年以来随着创新药发展迅速、BD交易火热，生物制药上游领域需 求快速修复，2024年中国市场规模212亿元，2024-2030E复合增速有望达到11.5%。竞争格局来看，国产 化率总体偏低，国产替代机会大。目前威高血净已建立起了生物制药上游过滤产品线，而威高普瑞在生 物制药拥有广泛的客户资源，交易后双方有望进一步发挥协同作用，充分把握生物制药上游市场机遇， 拓展未来增长空间。 公司医疗器械旗舰平台定位进一步明确 交易后，公司将持有威高血净52.10%股权，成为其控股股东并合并财务报表。本次交易将进一步整合 并优化威高品牌下的核心医疗资产，公司将成为威高集团旗下医疗器械的旗舰型平台。 风险提示 新业务拓展不及预期，业绩承诺未能完成的 ...